Shrinking the prostate before radiation for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests how well the hormone drug leuprorelin acetate shrinks the prostate before radiation therapy for men with prostate cancer. The goal is to make radiation safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man diagnosed with prostate cancer through a biopsy.
- You plan to get hormone therapy before starting radiation treatment.
- Your prostate must be at least 20 cc (about the size of a walnut) when measured at diagnosis.
- Your cancer has not spread to lymph nodes or other parts of the body on scans.
- You have not had radiation to the pelvic area in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a procedure called prostate artery embolization (PAE) can help shrink the prostate before radiation therapy. It may improve urinary symptoms for men with an enlarged prostate and high symptom scores.
This trial tests whether men with certain prostate cancer seen on MRI can safely receive a lower dose of radiation. The goal is to keep cancer control while possibly reducing side effects.
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
This trial tests a precise radiation treatment for prostate cancer that uses smaller safety margins to reduce side effects while still targeting the cancer effectively. It may be a good option for people with early-stage, low- or favorable intermediate-risk prostate cancer.
This trial tests a new radiation approach for prostate cancer that has not spread. It combines different types of radiation with or without hormone therapy to see if this approach works better with fewer side effects.
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.